Hematologic Malignancies

ASH 2025: Emerging Clinical Evidence and Pivotal Trials in Lymphoma: Key Insights Shaping Modern Practice

Explore recent pivotal trials in CLL, SLL, and high-risk MCL, highlighting next-generation BTK inhibitors, early CAR-T integration, and chemotherapy-sparing approaches. This synthesis provides clinicians with...

Latest Post

ASH 2025: Advances in Individualized Leukemia Care: Insights from GIMEMA and AUGMENT-101 Trials

Explore recent pivotal trials in AML and CLL, highlighting MRD-guided therapy, targeted agents, and chemotherapy-sparing...

ASH 2025: Optimizing MM Care: Key Trials and Consensus Updates on Targeted, Immune-Based, and Risk-Adapted Approaches

Explore recent pivotal trials and consensus updates in multiple myeloma, including MajesTEC-3, COBRA, and the...

FELIX Study: Long-Term Obe-cel CAR T-Cell Outcomes in Relapsed/Refractory B-Cell ALL

Obe-cel CAR T shows 54% 2-year remission rate in B-cell ALL; earlier treatment & Ph+...

Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results

Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response...

Circulating Tumor DNA Outperforms PET Imaging for Minimal Residual Disease Detection in Large B-Cell Lymphoma

ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans...

Dual CCR9/CD1a CAR-T Cell Therapy for T-ALL

CCR9 expressed on >70% of T-ALL patients; dual targeting CCR9/CD1a achieves 86% patient coverage while...

JNJ-5322 Trispecific Antibody Achieves 100% Response Rate in Relapsed/Refractory Multiple Myeloma Phase 1 Trial

Trispecific antibody JNJ-5322 achieves 100% response rate in R/R myeloma with improved oral toxicity vs...

RedirecTT-1 Trial: Talquetamab + Teclistamab for Multiple Myeloma with Extramedullary Disease

Combination bispecific antibodies achieve 79% response rate in multiple myeloma with extramedullary disease.

POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL

40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60,...

Hematologic Malignancies Insight Center

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest

Hematologic Malignancies

Latest Post

Hematologic Malignancies Insight Center

Multiple Myeloma (MM)

Acute Lymphoblastic Leukemia (ALL)

Non-Hodgkin Lymphoma